Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 2/20 | 0.55 |
| ▸ | CTSS | P25774 | 8/20 | 0.54 |
| ▸ | CTSL | P07711 | 7/20 | 0.54 |
| ▸ | CTSK | P43235 | 6/20 | 0.54 |
| ▸ | CTSB | P07858 | 5/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7300987 | 1.00 | ATM (0.56) | ATMELANECTSSCTSLCTSK | |
| SCHEMBL28216854 | 0.91 | CTSK (0.56) | ATMELANECTSSCTSLCTSK | |
| SCHEMBL7181654 | 0.90 | CTSS (0.57) | CTSSCTSLCTSKCTSB | |
| SCHEMBL7183454 | 0.90 | CTSS (0.57) | CTSSCTSLCTSKCTSB | |
| SCHEMBL4092509 | 0.89 | ELANE (0.51) | ATMELANECTSSCTSLCTSK | |
| SCHEMBL16834866 | 0.88 | ATM (0.56) | ATMELANECTSSCTSLCTSK | |
| SCHEMBL16846451 | 0.88 | ATM (0.56) | ATMELANECTSSCTSLCTSK | |
| SCHEMBL8211096 | 0.87 | CTSS (0.61) | ATMELANECTSSCTSLCTSK | |
| SCHEMBL7307319 | 0.87 | CTSS (0.61) | ATMELANECTSSCTSLCTSK | |
| SCHEMBL7307315 | 0.87 | CTSS (0.61) | ATMELANECTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0840614-A1 | CALPAIN INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI WINTHROP, INC. (US) | 1998-05-13 | — | — | EP | claimed |
| CN-1036832-C | Composition containing a penem or carbapenem artibiotic and the use of the same | SANKYO CO (JP) | 1997-12-31 | — | — | CN | claimed |
| WO-1996041638-A1 | CALPAIN INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI WINTHROP, INC. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | claimed |
| CN-110023474-A | Purposes, washing methods and utensil washing composition of the enzyme for washing | 诺维信公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-108025084-A | Antibody Drug Conjugates (ADC) and antibody prodrug conjugates (APDC) with enzyme cleavable groups | 拜耳医药股份有限公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-107921146-A | Spindle drives the antibody drug conjugate (ADC) of albumen (KSP) inhibitor and the antibody of anti-CD123 | 拜耳医药股份有限公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107635586-A | The antibody drug conjugate (ADC) of KSP inhibitor and not glycosyafated anti-TWEAKR antibody | 拜耳医药股份有限公司 | 2018-01-26 | — | — | CN | disclosed |
| EP-3233127-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096610-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| CN-1186434-A | Pharmaceutical composition containing protease inhibitor and monoglyceride | HOFFMANN LA ROCHE (US) | 1998-07-01 | — | — | CN | disclosed |
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| EP-0363284-B1 | Use of peptidase inhibitors for the preparation of medicaments useful for the treatment of strokes | MERRELL PHARMA INC (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5614533-A | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) | 1997-03-25 | — | — | US | disclosed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
| EP-0410411-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-30 | — | — | EP | disclosed |
| EP-0363284-A2 | Use of peptidase inhibitors for the preparation of medicaments useful for the treatment of strokes | MERRELL PHARMACEUTICALS INC. (US) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | ATM 4525/4885ELANE 527/4885CTSS 661/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ATM 4424/4885ELANE 19/4885CTSS 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.